4 completed, 3 recruiting, 2 active not recruiting, 2 not yet recruiting. 7 Phase 1, 4 Phase 2, 2 Phase 3.
Follow PF-07220060: new trials by email Literature Review of PF-07220060 trials Research Report on PF-07220060
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | Pfizer | 3800 | 2026-12-01 | 2026-10-22 |
| A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Pfizer | 268 | 2026-11-09 | 2026-10-28 |
| A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease Atirmociclib - Hepatic Impairment, Healthy, Hepatic Insufficiency | Phase 1 | Recruiting | Pfizer | 28 | 2026-06-29 | 2026-08-21 |
| A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 PF-07220060, Itraconazole, Probenecid - Healthy Adults | Phase 1 | Completed | Pfizer | 25 | 2025-09-22 | 2026-04-03 |
| A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants PF-07220060 - Healthy Participant | Phase 1 | Completed | Pfizer | 35 | 2025-08-14 | 2026-04-20 |
| A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060 PF-07220060, Carbamazepine ER Tablet - Healthy Adults | Phase 1 | Completed | Pfizer | 14 | 2025-03-21 | 2025-11-25 |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease PF-07220060, letrozole, abemaciclib - Breast Cancer | Phase 3 | Active not recruiting | Pfizer | 1035 | 2025-01-06 | 2026-10-16 |
| A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause PF-07220060, letrozole - Breast Cancer | Phase 2 | Completed | Pfizer | 121 | 2024-07-11 | 2026-07-15 |
| A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. vepdegestrant, PF-07220060 - Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Pfizer | 71 | 2024-02-19 | 2026-09-30 |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors PF-07248144, Fulvestrant, Letrozole - Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Pfizer | 320 | 2020-11-16 | 2026-10-21 |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors PF-07220060, Letrozole, Fulvestrant - Liposarcoma, Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 430 | 2020-09-23 | 2026-10-28 |
Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hepatic Insufficiency (1) · Liposarcoma (1) · Prostatic Neoplasms (1) · Recurrence (1) · Unilateral Breast Neoplasms (1)
Pfizer (11)
United States (9) · China (4) · Japan (4) · Australia (3) · Belgium (3) · France (3) · Slovakia (3) · South Korea (3) · Spain (3) · Argentina (2) · Canada (2) · Czechia (2) · Germany (2) · Italy (2) · Poland (2)
2023 (1)